Inventiva S.A. (NASDAQ:IVA) Short Interest Down 12.1% in May

Inventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 347,400 shares, a drop of 12.1% from the April 30th total of 395,400 shares. Based on an average trading volume of 15,800 shares, the short-interest ratio is currently 22.0 days. Approximately 1.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new position in Inventiva S.A. (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. TD Cowen started coverage on shares of Inventiva in a research note on Friday, February 21st. They issued a "buy" rating and a $10.00 price target for the company. HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of Inventiva in a report on Friday, March 28th. Finally, Guggenheim decreased their price target on Inventiva from $12.00 to $9.00 and set a "buy" rating on the stock in a research note on Friday, April 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Inventiva currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.40.

Inventiva Stock Up 3.3%

Shares of NASDAQ IVA traded up $0.11 during trading hours on Friday, hitting $3.52. The company's stock had a trading volume of 86,072 shares, compared to its average volume of 64,376. Inventiva has a 12 month low of $1.53 and a 12 month high of $4.05. The business has a 50-day simple moving average of $3.37 and a 200-day simple moving average of $2.84.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.